Clinical Trial Update: A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating adding linagliptin to premixed insulin to reduce glycemic variability and HbA1c in patients with Type 2 Diabetes Mellitus on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tradjenta (Linagliptin)

Snippet

Sponsor: Yanbing Li | Conditions: Type 2 Diabetes Mellitus, Peritoneal Dialysis | Phase 4 | Status: UNKNOWN